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Anthralin Inhibition of Mouse Epidermal Arachidonic Acid 
Lipoxygenase In Vitro* 
C HARLES J. BEDORD, PH.D ., JOHN M. YOUNG, PH.D., AND BONNIE M. WAGNER, B.S. 
Department of Shin Biology, Syntex Research, Palo Alto, California, U.S.A . 
Epidermal strips, free of sebaceous gland and hair 
follicle contamination, were prepared from mouse tail 
skin. Epidermal homogenates synthesized prostaglan-
dins a nd 12-hydroxy-5,8,10,14-eicosatetraenoic acid 
(12-HETE) from exogenously added [1- 14C]arachidonic 
acid. The effects of pH, assay time, substrate concentra-
t ion, a nd several selective inhibitors upon the lipoxy-
genase and cyclooxygenase pathways were determined. 
Ultracentrifugation of the crude homogenate at 105,000 
g sedimented both activities, and pellet 12-HETE syn-
thesis increased 2-fold r elative to the crude homogenate. 
Recombination of the 105,000 g pellet and supernatant 
gave y ields of prostaglandins and 12-HETE essentially 
equivale nt to that of crude homogenate. 
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Abbreviations: 
CDNQ: 6-chloro-2,3-dihydroxy-1,4- napht hoquinone 
DHAQ: 1,8-dihydroxy-9,10-ant hraquinone 
EGTA: ethyleneglycol-bis-{#-am inoethyl ether) -N ,N '- tetraacetic 
ac id 
GLC- MS: gas liquid chromatography- mass spectrometry 
HETE: hydroxyeicosatetrae noic ac id 
IC: inhibitory concentration 
NDGA: nordihydroguaiaretic acid 
PG: prostaglandin 
TLC: t hin -layer chromatography 
When tested in homogenate with 4.5 JLM arachidonic 
acid, anthralin specifically inhibited 12-HETE produc-
tion with IC5 0 of 50.0 JLM; no significant effect against 
cyclooxygenase was observed over the dose range of 2-
200 JLM. 1,8-Dihydroxy-9,10-anthraquinone (DHAQ) 
also specifically inhibited 12-HETE synthesis, but the 
dose response curve was flatter and maximum inhibition 
was only 55% at 200 JLM. 
6 - Chloro - 2,3 - dihydroxy - 1,4 - naphthoquinone 
(CDNQ), an agent with topical antipsoriatic activity, 
also inhibited 12-HETE synthesis with an IC50 of 25 JLM, 
but simultaneously stimulated prostaglandin produc-
tion, up to 2.5-fold at 200 JLM. 
When tested with washed human platelets, anthralin 
again specifically inhibited 12-HETE production with 
an IC5 0 of 10 JLM, while DHAQ inhibited lipoxygenase 
activity by only 40 % at 25 JLM. When tested in platelets, 
CDNQ gave 33% inhibition of 12-HETE production at 
200 JLM, although prostaglandin synthesis was stimu-
la ted over the range pf 25-200 JLM. It is proposed that 
certain antipsoriatic agents may exert their action 
through modulation of arachidonic acid metabolism. 
Epidermis possesses enzymes capable of metabolizing arach-
idonic acid into cyclooxygenase (PGF~ ... PGD2 , PGE2 ) and 
lipoxygenase (12-HETE) products [1 ,2]. While oxygenated ar-
achidonic acid products are clearly involved in inflammatory 
processes [3], their involvement in t issue homeostasis has not 
been established. In many inflammatory skin condit ions, re-
leased arachidonic acid is substantially metabolized via the 
cyclooxygenase pathway, resulting in dramatic elevations in 
prostaglandins (4,5]. Although lipoxygenase products were not 
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d etermined in t hese co ndi t ion s, t he sit uation in psorias is ap -
pea rs to be u nique s ince prostagla ndin leve ls a re minimally 
e levated, wh ereas free a rachidonic acid and 12-HETE a re e le-
vated 35-fold a nd 70-fo ld , respectively [6 ]. E levated amounts 
o f leukotriene B 4 have a lso been reported in p so riatic lesion s 
[7 ]. Indeed , t here is eviden ce to suggest that in t he psoriatic 
lesion a nd t he surrounding Woronoffs r ing, t he cyclooxygen ase 
resp onsible for prostagla ndin production is e it her inhibited or 
d efici ent [8 ] . 
S ince UVB, a standard t reatm ent for psorias is, stimulates 
prostagla ndin productio n in norm a l skin [5], we questioned 
whether t he a ntipso riatic efficacy of certain t reatments might 
be related to this ability a nd t he con sequentia l restoration of a 
b a la nce between lipoxyge nase a nd cyclooxygenase products 
wi t hin t he lesion . Accordingly, we investigated t he ab ility of 
m ouse epiderma l h omogen ates to metabolize exogen ous arach-
idonic ac id and examined the effects of two a nti p soriatic agents 
in t his system a nd a lso in a washed human plate let system. 
Our resul ts su ggest t hat a n t ipsoriatic activity may be re lated 
to inhibition of lipoxygen ase a nd/ or stimulation of cyclooxy-
genase product syn thesis. 
MATERIALS AND METHODS 
Prepa ration of Epidermal Homogenat.es and Washed Platelets 
Male and female Swiss Webster-derived mice (Simonsen Labs, Gil-
roy, Ca liforn ia), weighing 23- 27 g, were killed by cervical dislocation. 
Tails were removed and sli t lengthwise; the full-thickness skin was 
peeled off and incubated wit h agitation at 37' C for 30 min in Dulbecco's 
phosphate-buffered saline without Ca++ and Mg++, conta ining 20 mM 
EDTA, pH 7.4. Epidermal sheets, free of sebaceous glands and hair 
follicles, were peeled off the dermis wit h forceps and frozen in liquid 
ni trogen. Accumulated epidermal sheets were pulverized in liquid ni -
t rogen with a morta r and pestle and the powder was suspended in 0.1 
M phosphate buffer, pH 7.4 (50 mg wet weight/ml) . The resultant 
suspension was homogenized wi t h a Tissumizer homogenizer (Tekmar 
Company, Cincinnati , Ohio) at 4' C and aliquots of t he homogenate 
were placed in tubes for enzyme assay. 
Washed human platelets were prepared from blood drawn from 
healthy donors who had not taken medications for 2 weeks prior to 
collection. Blood was collected in 7.5% (v/ v) 77 mM EDTA and cent ri -
fu ged at 200 g for 15 min. The platelet-rich plasma was centrifuged at 
1,200 g for 15 min and the platelet pellet resuspended in 0.15 M 
NaC I:0.15 M Tris- HCI buffer, pH 7.4:77 mM EDTA (90:8:2 v/v/v) and 
centrifuged at 1,200 g for 15 min. T he washed platelet pellet was 
resuspended in assay buffer consisting of 0.1 M potassium phosphate 
buffer, pH 7.0, contain ing 1.0 mM EGTA and 10.0 mM glucose. Platelet 
counts were conducted with a model 921 Royco Cell Counter, (Royco 
Instruments, Houston, Texas). Aliquots containing 1 X 107 platelets 
were used for enzyme assays. 
Enzyme Assay Product Identification 
Compounds were dissolved in DMSO and added to epidermal ho-
mogenates of platelet suspensions to give final assay volumes of 1.0 mi. 
Final DMSO concentrations were 5% in epidermal homogenates and 
2.5% in platelet uspensions. Control samples contained either 5% or 
2.5% DMSO for the respective assays. Compounds were preincubated 
with the sample a liquots for 5 min at room temperature and assays 
were ini t iated by addition of 4.5 11M [1 -"C]arachidonic acid (New 
England Nuclear, 55.8 mCi/ mM) in 5 Iii of ethanol or sodium bicarbon -
ate solut ion. Assays were run for 10 min at 37'C, reaction mixtures 
were ac idified to pH 3.2, and the products were extracted twice with 
ethyl acetate. Products were analyzed by argentation t hin-layer chro-
matography (TLC) using t he method of Greenwald et al [9]. Thin-
laye r plates were scanned for radioactivity and appropriate areas 
scraped and coun ted by liquid scintillat ion. Samples conta ining boiled 
epidermal homogenate or platelet suspension, DMSO, and radioactive 
substrate served as background controls. Background radioactivity was 
subtracted from cyclooxygenase and lipoxygenase products formed by 
active epidermal or platelet samples. Prostaglandin radioactive peaks 
from epidermal homogenates were ident ified by coc hromatography with 
visua lized standards in 2 different TLC systems and by their selective 
inhibi t ion by naproxen and indomethacin. The 12- HETE produced by 
epidermal homogenates was ident ified by (1) elut ion of the radioactive 
area from t he TLC plate and subsequent analysis by combined gas 
liquid chromatography- mass spectrometry GLC- MS together wi th 5-
HETE, 15-HETE, and 12-HETE standards, and (2) by the relatively 
selective inhibi t ion produced by nordihydroguaiaretic ac id (NDGA) 
and phenidone and lack of inhibition by naproxen and indomethacin. 
The t hromboxane and 12-HETE products from plate let extracts were 
ident ified by comparison of the TLC nr va lues with those reported by 
Greenwald et al [9]. Unless otherwise indicated, all assay samples were 
run in duplicate. 
Assay of Epidermal Soluble a.nd Jn.solu.ble Protein Fractions 
The pulverized frozen powder of mouse epidermal strips was dis-
persed in assay buffer (0. 1 M phosphate buffer , pH 7.4; 100 mg wet 
weight/ ml) and homogenized as previously described. A portion of this 
crude homogenate was centrifuged at 105,000 g fo r 90 min at 4' C. The 
supernata nt was removed and the pellet gently resuspended to its 
original volume wit h assay buffer. When assayed individually, 0.5-ml 
aliquots o f the 105,000 g supernatant, resuspended pellet, and the 
centrifuged crude homogenate were each diluted to 1.0-ml volumes with 
buffer. For recombination experiments, 0.5 ml of t he resuspended pellet 
was added to 0.5 ml of t he supernatant. All assays were run with 4.5 
11M [1- 1'C]arachidonic ac id in a final volume of 1.0 ml at 37'C for 20 
min. Reaction mixtures were extracted and products analyzed as pre-
viously described. 
Estimation of E ndogenous Ara.chidonic Acid 
[1- 14C]Arachidonic acid (0.25 11Ci, 1.4 /-i g) was added to epidermal 
homogenate which had been previously homogenized in 
CH30H:CHCI:t:H20 (2:1:0.8). Lipids were extracted by the method of 
Bligh and Dyer [10], which extracts all but the most polar glycolipids, 
and total fatty acid methyl esters were prepa red by t ransesterification 
as described by Morrison and Smith [11]. The tetraenoic fatty ac id 
methyl ester fraction was purified by argentation TLC and eluted from 
the silica ge l. Product recovery was estimated by liquid scin t illation 
counting of the [1-14C]arachidonic acid inte rnal standard. Analysis of 
the tetraenoic methyl ester fraction by GLC showed a single peak 
which cochromatographed with methyl arachidonate standard. Endog-
enous arachidonic ac id was estimated by calculating t he GLC peak 
area, comparing the peak a reas produced by quantitative standa rds, 
and correcti ng for recovery based on t he in ternal radioactive standard. 
RESULTS 
Effects of pH, Assay Time, and S ubstrate Concentration 
Mouse ta il ep ide rmal homogen ates incubated with a rachi -
donic ac id syn t hesized products of bot h the lipoxygenase (12-
HETE) and cyclooxygen ase (PGF2,, PGE2, and PGD2) path-
ways. 12 -HETE synthes is showed a pH optimum of 7.4 and 
declined rapidly above pH 8.0 (Fig 1). Total prostaglandin 
synthesis was maximum at pH 6.0-7.6, but a n apparen t second 
pH m aJ{imum for cyclooxygenase was found at pH 9.0 (Fig 1). 
Conversion of [l -14 C]arachidon ic acid to lipoxygen ase a nd 
cyclooxygenase products by t he epidermal h omogen ate in -
creased rapidly unt il 10-min assay time, a fter which both rates 
dec reased s h a rply (Fig 2) . Ini t ia l reaction rates were not abso-
lutely linear with t ime, a lt hough linearity m ay exist at assay 
t imes between 0-2 min. When a 5-min assay time was used , 
prostag la ndin a nd 12-HETE syn t hetic rates increased with 
increasing [V'C]a rachidonic acid concentration (Fig 3). Dou-
ble rec iprocal plots gave approximate K , values of 8.3 11M a nd 
7.7 11 M for exogenous a rachidonic acid with respect to prosta-
gla ndin and 12-HETE formation . Ymux was calculated as 0.57 
nmol/5 min / ml homogenate for prostagla ndin syn t hesis and 
1.8 nmol/5 min / ml homogenate for HETE synthesis. 
Localization of Epidermal Cyclooxygenase and Lipoxygenase 
A port ion of t he mouse tai l epidermal h om ogen ate was sep-
a rated into 105,000 g soluble a nd p e llet fraction s. The fraction s 
were t h en assayed for prostaglandin and 12-HETE syn t hesizing 
activity separately a nd after recombination . In each case, t he 
a m ount of p e llet o r soluble protein fraction assayed after cen-
trifugation was t he same as the amoun t of t hat fraction found 
in a n assayed a liquot of t he crude homogenate. The resus-
pended 105,000 g pellet of t he epidermal homogen ate synt he-
s ized fa r m ore HETE a nd prostaglandin from [l- 1"1C]arac hi -
donic BC id t h a n did t he 105,000 g supernatant fraction (Table 
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FIG 1. Effect of pH on t he conversion of [1 -14C]arachidonic acid to 
12-HETE (solid symbols) and prostaglandins (PGFz,. + PGEz + PGD2, 
open symbols) by epidermal homogenates. Reactions were run for 20 
min in appropriate buffer systems (0.1 M), and 40,000 cpm aliquots of 
each reaction mixture were analyzed. Individual points represent the 
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F IG 2. Effect of assay t ime on the conversion of [1-"C]arachidonic 
acid to 12-HETE (e) and tota l prostaglandins (0), (PGF2 .. + PGE2 + 
PGDz) by epidermal homogenates. Reaction mixtures were assayed in 
0.1 M potassium phosphate buffer pH 7.4, with 4.5 JLM [1 -"C]arachi -
donic acid, and 80,000 cpm aliquots were analyzed. Individual points 
represent the range of 2 determinations, except the values at 10 min 
and 20 min, which represent the mean and SE of 3 determinations. 
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FIG 3. Effect of the concentration of [1 -"C]arachidonic ac id on the 
rate of conversion to total prostaglandins (PGF2 .. + PGE2 + PGD2 ) (A) 
a nd 12-HETE (B) by epidermal homogenates. Reaction mixtures were 
assayed for 5 min in 0.1 M potassium phosphate buffer pH 7.4 , wi t h 
varying amounts of [l -1'1C]arachidonic ac id (55 .8 mCi/mM), and 80,000 
cpm aliquots were analyzed. Each point represents a single determi -
nation. 
1) . Removal of the supernatant from the pellet increased lipox-
ygenase activity of the pellet 2-fold relative to the crude ho-
mogenate or a recombination of the 105,000 g pellet plus 
supernatnant (Table I) . The 105,000 g soluble inhibitor of 
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HETE biosynthesis appears to be heat stable, but can be 
removed by dialysis. 
Effects of Inhibitors and Cofa.ctors 
The effects of various inhibitors and cofactors upon the 
cyclooxygenase and lipoxygenase pathways were originally de-
termined at pH 8.0; the effects of naproxen, phenidone, and 
epinephrine were later assayed at pH 7.4. Prostaglandin syn-
thesis by epidermal homogenates was specifically inhibited by 
cyclooxygenase-directed agents such as indomethacin and na-
proxen (Table II). The semiselective lipoxygenase inhibitors 
phenidone and nordihydroguaiaretic acid (NDGA) strongly 
inhibited HETE synthesis and showed a lesser effect against 
cyclooxygenase products. Epinephrine and hydroquinone in-
hibited HETE synthesis and simultaneously stimulated cy-
clooxygenase products. Addition of reduced glutathione inhib-
ited both pathways. 
Effects of Antipsoriatic Agents on Epidermal Enzymes 
Incubations of crude epidermal homogenates carried out in 
the presence of anthralin resulted in a concentration-dependent 
inhibition of HETE synthesis (Fig 4), with no consistently 
s ign ificant effect on prostaglandin synthesis over the range of 
2- 200 ,uM anthralin . In these experiments, anthralin exhibited 
an ICw of 50.0 ,uM (range 33- 55 ,uM) against the lipoxygenase 
pathway. As a control, we also tested 1,8-dihydroxy-9,10-an-
thraqu inone (DHAQ), which has been reported to be ineffective 
against psoriasis [12], although it is one of the primary metab-
TABLE I. Localization of HETE and PC synthesizing activity within 
the epidermal homogenate 
Fraction 
Homogenate 
105,000 g pellet 
105,000 g supernatant 
105,000 g pellet + super-
natant 
% Conversion into products" 
PG 
13.1 ± 0.2 
10.6 ± 0.2 
1.3 ± 0.2 
8.9 ± 0.1 
HETE 
22.5 ± 0.4 
54.9 ± 2.4 
5.0 ± 0.7 
28.9 ± 1.6 
"Results indicate the percentage of 40,000 cpm aliquots recovered 
in products (mean ± SE, n = 4). 
TABLE II. Effects of inhibitors and cofactors on synthesis of 12-HETE 
and prostaglandins by epidermal homogenates" 
Con- Percent of control• 
Agent cen -
tration HETE PG 
Indomethacin 50 pM 90 10 
Naproxen 50 pM 100 [103]' 31 [31] 
Phenylbutazone 50 pM 93 74 
Nordihydroguaiaretic acid 50 pM 9 50 
Phenidone 50 pM 15 [40] 76 {73] 
Hydroquinone 0.2 mM 33 137 
0.5 mM 21 134 
1.0 mM 17 118 
2.0 mM 5 119 
Epinephrine 0.2 mM 68 196 
0.5 mM 72 218 
1.0 mM 69 [55] 268 [241] 
2.0 mM 66 246 
Glutathi one 0.2 mM 85 95 
0.5 mM 71 65 
1.0 mM 73 68 
2.0 mM 79 55 
"Samples were assayed with 4.5 pM (1-'"'C]arachidonic acid at pH 
8.0. 
1
' Control samp les contained homogenate, substrate, and vehicle 
without agent. Results represent the average of 2 determinations for 
each sample. 
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FrG 4. Inhibition of 12-HETE synthesis by anthralin (•) and 
DHAQ (0). Control samples incorporated 9071 ± 137 SE cpm, n = 8, 
into HETE when 70,000 cpm were analyzed by TLC. The individual 
points represent the range of 2 determinations, except the values at 
100 pM , which represent the mean and SE of 4 determinations. 
oli tes of anthralin in the epidermis [13,14). This compound 
similarly showed a specific inhibition of the lipoxygenase path-
way, but in this case, tbe dose response curve was flatter than 
that for anthralin and the maximum inhibition was only about 
55% (Fig 4). 
The drug 6-chloro- 2,3 -dihydroxy-1,4- naphthoquinone 
(CDNQ), which has been recently demonstrated to be effective 
against psoriasis (data on file at Syntex Research) , also inhib-
ited HETE synthesis, but concurrently stimulated prostaglan-
din production (Fig 5). HETE synthesis decreases between 1 
,uM and 25 ,uM concentrations of CDNQ, with approximately 
50% i11hibition occurring between 25 11M and 100 11M and 70% 
inhibition at 400 ,uM. The dose-dependent stimulation of pros-
taglandin synthesis results in a maximum 160% increase in 
cyclooxygenase products at 200 11M concentration. 
In order to determine whether the inhibition of 12-HETE 
synthesis by CDNQ resulted from direct inhibition of the 
lipoxygenase pathway, or a diversion of [l- 14C)arachidonic acid 
substrate away from HETE production due to stimulation of 
the cyclooxygenase system, epidermal homogenates were pre-
treated with naproxen prior to addition of CDNQ. When as-
sayed with [V'C]arachidonic acid, 12-HETE production was 
still inhibited (Table III), thus demonstrating that lipoxygenase 
inhibition by CDNQ does not result from increased competition 
for substrate from a stimulated cyclooxygenase system. 
Whereas the above results with anthralin, DHAQ, and 
CDNQ had been obtained using 4.5 ,uM [V"'C]arachidonic acid 
substrate, an experiment was conducted to determine whether 
these compounds would have similar effects on the epidermal 
lipoxygenase and cyclooxygenase systems when a substrate 
concentration well above the estimated K, for exogenous sub-
strate of both pathways was used. The results of an experiment 
utilizing 20 ~~M [1 -HC]arachidonic acid showed that anthralin 
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FIG 5. Effects of CDNQ on the synthesis of total prostaglandins 
(PGF2, + PGE2 + PGD2) and HETE from [1 -"C]arachidonic acid. 
Control samples incorporated 4338 ± 236 SE cpm, n = 4, into prosta-
glandins and 7819 ± 124 SE cpm, n = 4, into HETE when 60,000 cpm 
were analyzed by TLC. The individual points represent the range of 2 
determinations, except the values at 400 !lM and 100 !lM which repre-
sent the mea n and SE of 4 determinations. 
TABLE Ill. Effect of naproxen pretreatment on the inhibition of 
HETE synthesis by 6-chloro-2,3-dihydroxy- 1,4-naphthoquinone 
(CDNQJ in epidermal homogenates" 
Sample(s) Treatment % Total pc• % HETE # 
1 Control 8.9 ± 0.2 16.8 ± 0.6 
2 CDNQ (200 J.LM) 20.7, 20.5 5.9, 6.0 
3 Naproxen (50 J.LM) 2.6, 2.2 18.0, 15.7 
4' Naproxen (50 !lM) + 2.7, 2.8 3.5, 3.2 
CDNQ (200 J.LM) 
" Assays conducted for 10 min at pH 7.4, with 4.5 J.LM [1-" C]arachi-
do nic acid. 
b Percentage of 70,000 cpm aliquots recovered in products. Sample 
#1 values represent mean ± SE, (n = 4). Other values are individual 
results from duplicate assays. 
'Sample was preincubated 5 min with naproxen and then 5 min 
with CDNQ prior to assay. 
and DHAQ remained specific inhibitors of 12-HETE synthesis, 
while CDNQ continued to inhibi t t he lipoxygenase pathway 
while stimulating cyclooxygenase activity Table IV). 
Effects of Antipsoriatic Agents on Platelet Enzymes 
When washed human platelets were incubated with 4.5 J.LM 
[V 4C]arac hidonic acid fo llowing pretreatment wi th ant hra lin , 
a dose-dependent inhibition of 12-HETE synthesis occurred, 
without any consistent effect on t he synthesis of total cycloox-
ygenase products (thromboxane + PGE2 + PGD.) (Table V). 
The synthesis of 12-hydroxyheptadecatrienoic acid during t he 
experiment was small enough that a radioactive peak for t his 
product, sufficiently resolved from t he [1-' ''C]arachidonic acid 
peak, cou ld not be obta ined after TLC. DHAQ also gave selec-
t ive inhibit ion of HETE synthes is ; however, t he effect at 25 
!lM was substant ia lly less t han t hat of ant hralin . CDNQ inhib-
ited the platelet lipoxygenase pathway and stimulated total 
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TABLE IV. Effect of agents on the synthesis of HETE and total PC by 
epidermal homogenates at 20.0 J.LM {1-"C}arachidonic acid substrate 
concentration" 
% of Control 
Agent I'M' 
PG HETE 
Anthralin 5 108, 154 91, 95 
50 117, 131 57, 70 
100 118±6 36 ± 2 
CDNQ 2 165, 175 43, 45 
50 204, 218 34, 38 
100 243 ± 14 24 ± 1 
DHAQ 5 91, 95 81,86 
50 94, 107 47, 55 
100 98 ± 2 44 ± 1 
CDNQ = 6-chloro-2,3-dihydroxy-1,4-naphthoquinone; DHAQ = 1,8-
dihydroxy-9,10-anthraquinone . 
"Assays conducted for 10 min at pH 7.4 . Control samples incorpo-
rated 10,030 ± 178 SE, (n = 6), into HETE and 3881 ± 126 SE cpm, 
(n = 6), into prostaglandins when 120,000 cpm were analyzed. 
"Values at 100 J.LM indicate mean ± SE, (n = 3). Other values are 
individual resul ts of duplicate assays. 
TABLE V. Effect of agents on the synthesis of HETE and 
cyclooxygenase products by intact, washed platelets" 
Con- % Control 
Compound cen-tration PC+ T~B, HETE (I' M) 
Anthralin 2 83 106 93 103 
5 105 101 66 87 
10 91 102 48 49 
25 118 120 30 30 
DHAQ 2 91 93 88 90 
5 99 112 79 83 
10 87 91 61 71 
25 86 94 61 62 
CDNQ 25 132 149 79 100 
50 168 175 90 97 
100 167 182 68 79 
200 187 187 66 69 
TXB2 = thromboxane B2; DHAQ = 1,8-dihydroxy-9,10-anthraqui -
none; CDNQ = 6-chloro-2,3-hydroxy-1,4-naphthoquinone. 
"Assays conducted for 10 min with 4.5 J.LM [1 -14C]arach idonic ac id. 
Control samples incorporated 43,000 ± 2235 SE cpm, (n = 10), in to 
HETE and 3541 ± 151 SE cpm, (n = 10), into cyclooxygenase products 
when 120,000 cpm were analyzed. 
cyclooxygenase product synthes is in a dose-dependent manner 
(Table V) . 
DISCUSSION 
The synthesis of prostaglandins from exogenous [1 -1''C]ar-
achidonic acid by epidermal homogenates has been previously 
described [1 ,15,16]. Human epidermis produced primarily PGE2 
and PGF2" [1 ,15], while rat epidermal microsomes synthesized 
PGE2 , PGF2"' and PGD2 [16]. Gu inea pig epidermal homage-
nates synthesized PGD2 as the principle cyclooxygenase prod-
uct, with smaller amoun ts ofPGE2 and PGF2"also being formed 
[17]. Minor amoun ts of PGh and t hromboxane A2 production 
by epidermal homogenates have been reported [1 ,17]. 
In addition to cyclooxygenase products, epidermal homage-
nates incubated with [1-' 4C]arachidonic acid form lipoxygen -
ase-derived 12-HETE from human epidermis [1] and X-HETE 
from gu inea pig epidermis [17] . Epidermal cyclooxygenase ac-
t ivity resides in a 105,000 g insoluble fraction of homogenates 
[15,16], while lipoxygenase solubility cha racteristics have not 
been characterized. 
The current study assayed the simultaneous conversion of 
[1 - '4C]arachidonic acid to cyclooxygenase (PGE~, PGD~, and 
PGF2,.) and lipoxygenase (12-HETE) products by homogenates 
of mouse tail skin epidermis. Because epidermal homogenates, 
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rather t han solubilized enzymes were used for assays, kinetic 
cha racteristics of t he enzy me systems are difficul t to determine 
a nd interpret. Problems may include loca lized high concentra-
tions of particulate suspens ion wit hin t he test tube, or differ-
ences in t he rates of metabolism between [1- ' ·'C] a rachidonic 
acid molecules which a re bound on the surface of epidermal 
fragments a nd t hose molecules which may diffuse into and be 
metabo lized wit hin t he fragment interior. Biochemical analys is 
of t he epiderm al homogenate showed that each 1.0-ml assay 
could be ex pected to contain approximately 7.8 p.g of endoge-
nous arachidonic acid (corresponding to 25.1 p.M) which may, 
to some degree, be available for cyclooxygenase or lipoxygenase 
metabolism, depending on t he amount released by hydrolys is. 
However , for t he purpose of determining kinetic parameters of 
t he ep iderma l assay system, possible release and ut ilization of 
endogenous arachidonic acid was ignored. 
The 12- lipoxygenase of blood platelets is generally considered 
to be a 105,000 g oluble enzyme [18) a lt hough some part iculate 
form may exist [19] . The lipoxygenase activity of t he ep idermis 
resided primarily in t he 105,000 g pellet fraction of t he cent ri -
fu ged homogenate, while t he supernatant retained only a small 
amount of ac tivity. While a true epiderma l membrane-bound 
lipoxyge nase may ex ist, two other poss ibili ties could a lso ac-
coun t for t his findin g: (1) t he freeze-thaw process and subse-
quent homogenization used to create t he epidermal homogenate 
may have caused soluble lipoxygenase enzyme to bind to epi-
dermal fragments which pellet upon cent rifugation; or (2) the 
12-HETE synthesizing capacity of t he 105,000 g pellet may 
result from a cytochrome P-450 oxygenation system simila r to 
t hat found in rat live r microsomes [20). Such a system, however, 
produces a wide variety of hydroxylation products from [1 -' ''CJ 
a rachidonic acid, including both 12-HETE and 15-HETE 
[20]. Ana lysi of the epidermal lipoxygenase product by com-
bined GC-M S, and compar ison to appropriate standards, 
showed t he product to be exclus ively 12-HETE. The possibility 
of 12-HETE biosynthesis by some form of P -450 cytochrome 
system, however, cannot yet be excluded. 
The clinically active antipsoriatic agents a nt hralin and 
CDNQ were very specific inhibitors ofHETE biosynthesis . The 
fact t hat DHAQ also showed some activity appears to dispute 
a ny cla im that spec ific inhibi tors of t he lipoxygenase pathway 
will necessarily show clinical activ ity against psoriasis. While 
inhibit ion of t he lipoxygenase pathway may be one necessary 
capabi li ty for beneficia l age nts to possess, other factors may be 
involved. It is unknown whether t he clinical efficacy of an-
t hra lin results from anthralin itself or a molecule resulting 
from its oxidation or biotra nsformation in the skin [14). T op-
ically applied a nt hralin probably binds to a lbumin proteins 
yielding DHAQ as t he principle oxidation product, although 
unoxidized anthra lin may exist in the skin 24 h after topical 
application [14). 
The general effects of a nthralin , CDNQ and DHAQ on 
platelet cyclooxygenase and lipoxygenase pathways were t he 
same as they were in the epidermal system; t herefore, these 
age nts do not appear specific fo r t he epidermis even t hough 
a nt hralin a nd CDNQ are topical ant ipsoriatics. 
The mechanism of lipoxygenase pathway inhibit ion resul t ing 
from anthralin, DHAQ, and CDNQ, and the reason for a 
simul taneous stimulation of prostaglandin synthesis with the 
latter compound is under investigation. While some form of 
competit ive inhibit ion is a possibili ty, these substances may 
a lso act by a ltering t he oxidation state of t he assay homogenate 
through scavenging of free radicals and reducing the levels of 
hydroperoxy acids in t he reaction mixtures [21). Such a mech-
anism could a lso expla in t he manner in which the free radical 
scavengers hydroquinone and epinephrine, and t he reducing 
agent, glutathione, can modulate t he synt hesis of prostaglan-
dins and 12-HETE by epiderma l homogenates. 
Defi nite conclusions concerning t he significa nce of t he in 
vitro inhibit ion of HETE synthes is by anthralin requires fur-
t her studies; however, it is clear t hat 12-HETE is a strong 
chemotactic agent for infl ammatory cells [22], and any reduc-
tion of t he elevated levels of t hi s compound in psoriatic lesions 
wou ld remove a factor contribut ing to t he chronic invasion of 
lesions by int1ammatory cells. Whether HETE compounds 
directly affect ep idermal homeostasis is not yet known. 
We thank Diane Cho and Michael Flanagan for their assistance in 
the analysis of lipoxygenase products with gas liquid chromatography-
mass spectroscopy. 
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